Clinical trial
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants
NCT00753649 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- September 23, 2008
- Completion date
- March 12, 2013
- Enrollment
- 224 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
acellular pertussis, diphtheria, haemophilus influenzae type b, hepatitis b, poliomyelitis, tetanus